Galectin Therapeutics Inc Net Assets
Galectin Therapeutics Inc net assets. Based on the latest financial reports, Galectin Therapeutics Inc (GALT) has net assets worth $-130.24 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.76 Million) and total liabilities ($146.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Galectin Therapeutics Inc (GALT) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-130.24 Million |
| % of Total Assets | -826.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | -4923.97% |
| 10-Year Change | -1150.31% |
| Growth Volatility | 671.54 |
Net Assets of Galectin Therapeutics Inc (2000–2025)
Net assets of Galectin Therapeutics Inc from 2000 to 2025. This chart illustrates how Galectin Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See GALT equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Galectin Therapeutics Inc (2000–2025)
The table below shows the annual net assets of Galectin Therapeutics Inc from 2000 to 2025. For live market cap and overall valuation, see GALT company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-126.19 Million | -22.44% |
| 2024-12-31 | $-103.07 Million | -71.10% |
| 2023-12-31 | $-60.24 Million | -87.12% |
| 2022-12-31 | $-32.19 Million | -1330.66% |
| 2021-12-31 | $2.62 Million | -89.19% |
| 2020-12-31 | $24.19 Million | -46.94% |
| 2019-12-31 | $45.59 Million | +560.99% |
| 2018-12-31 | $6.90 Million | +478.21% |
| 2017-12-31 | $1.19 Million | -90.07% |
| 2016-12-31 | $12.02 Million | -52.03% |
| 2015-12-31 | $25.05 Million | -10.46% |
| 2014-12-31 | $27.97 Million | +240.03% |
| 2013-12-31 | $8.23 Million | +3.92% |
| 2012-12-31 | $7.92 Million | +80.05% |
| 2011-12-31 | $4.40 Million | +359.56% |
| 2010-12-31 | $-1.69 Million | +62.08% |
| 2009-12-31 | $-4.47 Million | -852.45% |
| 2008-12-31 | $-469.00K | +83.96% |
| 2007-12-31 | $-2.92 Million | -13190.91% |
| 2006-12-31 | $-22.00K | -100.61% |
| 2005-12-31 | $3.58 Million | -64.54% |
| 2004-12-31 | $10.11 Million | +32.54% |
| 2003-12-31 | $7.62 Million | +371.68% |
| 2002-12-31 | $1.62 Million | +32.94% |
| 2001-12-31 | $1.22 Million | +2331.69% |
| 2000-12-31 | $50.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Galectin Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43235600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Galectin Therapeutics Inc Net Assets Breakdown (December 2025)
Galectin Therapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $65.00K | % |
| Other Components | $306.29 Million | % |
| Total Equity | $-126.19 Million | 100.00% |
Galectin Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Galectin Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Career Technology MFG Co Ltd
TW:6153
|
$316.68 Million |
|
Pondy Oxides & Chemicals Limited
NSE:POCL
|
$316.77 Million |
|
National Fertilizers Limited
NSE:NFL
|
$316.89 Million |
|
Dalian Zhiyun Automation Co Ltd
SHE:300097
|
$317.10 Million |
|
Lootom Telcovideo Network Wuxi Co Ltd
SHE:300555
|
$316.66 Million |
|
Guangdong Fangyuan Environment Co. Ltd. A
SHG:688148
|
$316.53 Million |
|
BLD Plantation Bhd
KLSE:5069
|
$316.49 Million |
|
Regional Management Corp
NYSE:RM
|
$316.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Galectin Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -103,070,000 to -126,195,000, a change of -23,125,000.
- Net loss of 30,836,000 reduced equity.
- Dividend payments of 138,000 reduced retained earnings.
- Share repurchases of 667,000 reduced equity.
- New share issuances of 3,235,000 increased equity.
- Other factors increased equity by 5,281,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-30.84 Million | -24.44% |
| Dividends Paid | $138.00K | -0.11% |
| Share Repurchases | $667.00K | -0.53% |
| Share Issuances | $3.23 Million | +2.56% |
| Other Changes | $5.28 Million | +4.18% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Galectin Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $0.02 | $3.35 | x |
| 2001-12-31 | $0.54 | $3.35 | x |
| 2002-12-31 | $0.59 | $3.35 | x |
| 2003-12-31 | $2.14 | $3.35 | x |
| 2004-12-31 | $2.35 | $3.35 | x |
| 2005-12-31 | $0.79 | $3.35 | x |
| 2006-12-31 | $0.00 | $3.35 | x |
| 2007-12-31 | $-0.45 | $3.35 | x |
| 2008-12-31 | $-0.06 | $3.35 | x |
| 2009-12-31 | $-0.56 | $3.35 | x |
| 2010-12-31 | $-0.18 | $3.35 | x |
| 2011-12-31 | $0.37 | $3.35 | x |
| 2012-12-31 | $0.52 | $3.35 | x |
| 2013-12-31 | $0.49 | $3.35 | x |
| 2014-12-31 | $1.28 | $3.35 | x |
| 2015-12-31 | $1.04 | $3.35 | x |
| 2016-12-31 | $0.41 | $3.35 | x |
| 2017-12-31 | $0.03 | $3.35 | x |
| 2018-12-31 | $0.18 | $3.35 | x |
| 2019-12-31 | $0.87 | $3.35 | x |
| 2020-12-31 | $0.42 | $3.35 | x |
| 2021-12-31 | $0.04 | $3.35 | x |
| 2022-12-31 | $-0.54 | $3.35 | x |
| 2023-12-31 | $-1.00 | $3.35 | x |
| 2024-12-31 | $-1.65 | $3.35 | x |
| 2025-12-31 | $-1.97 | $3.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Galectin Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-189.97%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -380.00% | 0.00% | 0.00x | 4.60x | $-195.00K |
| 2001 | -326.54% | 0.00% | 0.00x | 1.45x | $-4.09 Million |
| 2002 | -227.57% | 0.00% | 0.00x | 1.41x | $-3.84 Million |
| 2003 | -63.92% | 0.00% | 0.00x | 1.05x | $-5.64 Million |
| 2004 | -71.05% | 0.00% | 0.00x | 1.10x | $-8.19 Million |
| 2005 | -182.64% | 0.00% | 0.00x | 1.39x | $-6.90 Million |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.19 Million |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.14 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.10 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.02 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.46 Million |
| 2011 | -248.24% | 0.00% | 0.00x | 1.50x | $-11.35 Million |
| 2012 | -122.21% | 0.00% | 0.00x | 1.21x | $-10.47 Million |
| 2013 | -146.93% | 0.00% | 0.00x | 1.30x | $-12.91 Million |
| 2014 | -56.44% | 0.00% | 0.00x | 1.06x | $-18.59 Million |
| 2015 | -79.95% | 0.00% | 0.00x | 1.05x | $-22.53 Million |
| 2016 | -178.41% | 0.00% | 0.00x | 1.31x | $-22.64 Million |
| 2017 | -1360.85% | 0.00% | 0.00x | 3.49x | $-16.35 Million |
| 2018 | -201.51% | 0.00% | 0.00x | 1.31x | $-14.59 Million |
| 2019 | -29.16% | 0.00% | 0.00x | 1.06x | $-17.85 Million |
| 2020 | -96.99% | 0.00% | 0.00x | 1.22x | $-25.88 Million |
| 2021 | -1166.93% | 0.00% | 0.00x | 15.99x | $-30.79 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-35.56 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-35.04 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-36.74 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.22 Million |
Industry Comparison
This section compares Galectin Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Galectin Therapeutics Inc (GALT) | $-130.24 Million | -380.00% | N/A | $316.67 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhos… Read more